Yashara Biosciences was founded by research scientists and software engineers who shared the experience of watching excellent science be constrained by inadequate tools. We decided to do something about it.
The life sciences software industry has a structural problem. The largest vendors in the space — laboratory information systems, electronic lab notebook providers, compliance management platforms — were built for the enterprise market and subsequently adapted for scientific use. The adaptation is always imperfect. The result is software that asks the investigator to conform to the software's model of the world rather than the reverse.
At the same time, the open-source scientific software ecosystem — ImageJ, CellProfiler, R/Bioconductor, Python — has produced tools of genuine excellence, built by scientists for scientists. But open-source tools exist in perpetual tension between capability and accessibility. They are often not deployable at institutional scale without substantial informatics infrastructure. They rarely come with support, documentation, or the reliability guarantees that a clinical laboratory operating under CLIA obligations requires.
Yashara Biosciences was founded to occupy the space between these two failure modes: software with the domain specificity and scientific depth of the best open-source tools, and the institutional deployability, support infrastructure, and long-term maintenance commitment of commercial software. Built by people who have used microscopes and pipettes and CLIA compliance checklists in practice — not by product managers working from customer surveys.
We are deliberate about scope. We do not build general-purpose laboratory software and call it life-sciences-specific. We identify a specific domain where the existing tooling is genuinely inadequate for the scientists who depend on it, and we build something better for exactly that domain. FluorocellAI for cell imaging analysis. ComplianceCall for CLIA regulatory compliance. PuroChem for chemical hazard intelligence. Each domain addressed on its own terms. One design philosophy.
We do not build general-purpose tools with a thin layer of domain adaptation. The cell biologist's segmentation workflow and the compliance officer's audit trail are not variations on the same problem. Each Yashara product is built as if it were the only thing we make — informed entirely by the specific demands of its domain and the specific people who work in it. The price of this approach is a narrower market. The benefit is software that actually works for the people it was built for.
Laboratory workflows cannot be interrupted by disruptive UI redesigns, breaking API changes, or a vendor's decision to discontinue a product line. We version all public interfaces and deprecate nothing without a minimum two-year notification period. We design for five-year deployment horizons. When a core facility installs FluorocellAI, the macros and pipelines they build around it should still work without modification when they upgrade to the next major version. This is a harder engineering problem than moving fast and breaking things. We consider it non-negotiable.
The majority of the world's cell biology research is not conducted at institutions with unlimited informatics budgets. A single-investigator laboratory at a regional university doing rigorous, publishable science should have access to the same quality of segmentation tooling as a pharmaceutical company's imaging core facility. This is not a charitable position — it is a market observation. If the tool is only accessible to large institutions, we have chosen a market that excludes most of the scientists who would benefit from it. FluorocellAI's pricing architecture was designed explicitly to be within the indirect cost budget of a standard NIH R01 award.
ImageJ, Fiji, CellProfiler, OMERO, R/Bioconductor, Python — the open-source scientific software ecosystem represents decades of accumulated domain knowledge encoded in software. We do not ask users to abandon that ecosystem when they adopt Yashara products. FluorocellAI extends ImageJ; it does not replace it. ComplianceCall integrates with existing regulatory data sources rather than requiring manual re-entry. PuroChem exposes a REST API so it can be embedded in existing EHS management systems. Our job is to make the existing ecosystem better, not to extract users from it.
We validate our models against publicly available benchmark datasets and report the results transparently, including comparisons to alternative approaches. We document our methods with the same specificity we would expect of a published methods section. We do not make claims about performance that we cannot substantiate with reproducible benchmark experiments. When we do not know something — when our model performs unexpectedly on an unusual cell morphology, when a regulatory interpretation is uncertain — we say so explicitly rather than obscuring the limitation.
We think it is worth being explicit about the scope of our work, because the life sciences software market is crowded with vendors who describe themselves in expansive terms and deliver narrow value.
We do not provide an ELN, a LIMS, a sample management system, or an inventory management platform outside the context of our specific products. These are large, well-served markets. We are not in them. Our inventory management module exists within ComplianceCall specifically because CLIA compliance requires reagent traceability — not because we are building a general-purpose inventory platform.
FluorocellAI is designed for research cell biology and high-content screening in academic, government, and preclinical industrial laboratory settings. It is not an FDA-cleared in vitro diagnostic device and should not be used as the analytical basis for clinical diagnostic decisions. ComplianceCall supports laboratory CLIA compliance — it is not a GCP compliance platform for clinical trials.
Every feature request we receive that is outside the core scope of one of our products receives serious consideration and a polite decline if it would pull the product away from the depth of coverage we consider essential. We would rather do a small number of things exceptionally well than many things adequately. Our users rely on us for depth, not breadth.
Yashara Biosciences is a focused, founder-led company. Our products are built and maintained by a small team of scientists and engineers who are personally invested in their quality. This means our support is handled by the people who built the product, our design decisions are made by people who have done the work the software supports, and our roadmap is driven by scientific need rather than quarterly earnings targets.
Every Yashara product has been developed with the direct participation of domain experts who use the tools in their own work. We do not build in isolation and seek validation after the fact — our advisors are involved from the earliest design stages through product release and beyond. The following disciplines are represented in our scientific advisory network:
Software that supports scientific research and clinical laboratory operations carries responsibilities that consumer software does not. A segmentation error in a high-content drug discovery screen could misdirect a research program. A compliance documentation gap in a clinical laboratory could contribute to a patient safety incident. A missed chemical reclassification could expose laboratory personnel to hazards they were not informed of. We take these downstream consequences seriously.
For FluorocellAI, this means we validate our segmentation models rigorously, report our performance metrics transparently including failure modes, and are explicit about the cell types and imaging conditions where our models have been validated and where they have not. We do not claim universal applicability.
For ComplianceCall, this means we maintain connections to regulatory sources with the care and accuracy that clinical laboratory operations require, we do not interpret ambiguous regulatory language unilaterally, and we route uncertain regulatory questions to our advisory network of practicing CLIA consultants before encoding interpretations in the platform.
For PuroChem, this means we source toxicological data from primary regulatory publications and peer-reviewed studies, we document the source and date of every data point in our database, and we are explicit about the limitations of available toxicological data — including the many chemicals for which the toxicological evidence base is incomplete or contested.
Whether you have a question about a product, a scientific problem you think we might be able to help with, or feedback on work you have done with our tools — our scientific staff reads and responds to every substantive inquiry.